MS app data reveals how patients stick to their kesimpta schedule
NCT ID NCT05090033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well people with relapsing multiple sclerosis (RMS) follow their Kesimpta (Ofatumumab) treatment plan. Researchers used data from the MSGo patient support app to track when doses were taken. They also compared how patients felt (reported symptoms) with their actual medical results. The study included 103 adults and was completed by Novartis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Concord, New South Wales, 2139, Australia
-
Novartis Investigative Site
Southport, Queensland, 4222, Australia
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Heidelberg, 3084, Australia
-
Novartis Investigative Site
St Leonards, 2065, Australia